Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6122504 | 0.82 | PIM1 (0.39) | PIM1PIM3PIM2SLC6A4TIPARP | |
| SCHEMBL6121328 | 0.81 | PIM1 (0.35) | PIM1PIM3PIM2SLC6A4TIPARP | |
| SCHEMBL6121322 | 0.81 | LOXL2 (0.42) | — | |
| SCHEMBL8544620 | 0.79 | LOXL2 (0.41) | PIM1PIM3PIM2SLC6A4TIPARP | |
| SCHEMBL9893890 | 0.78 | GPR119 (0.44) | CACNA1HP2RX3P2RX2 | |
| SCHEMBL9893726 | 0.75 | PIM1 (0.33) | PIM1PIM3PIM2SLC6A4TIPARP | |
| Trifluoroacetic Acid SCHEMBL6121912 | 0.71 | P2RX7 (0.39) | PIM1PIM3PIM2TIPARPP2RX7 | |
| SCHEMBL8545951 | 0.69 | LOXL2 (0.42) | PIM1PIM3PIM2SLC6A4TIPARP | |
| SCHEMBL14707728 | 0.68 | CACNB4 (0.38) | CACNA1H | |
| SCHEMBL31435068 | 0.68 | MALT1 (0.47) | PIM1PIM3PIM2SLC6A4TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640506-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190135813-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2015-03-26 | — | — | US | disclosed |
| US-8933085-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640506-B2 | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | JAK2, JAK1, JAK3 | PIM1 700/4885PIM3 950/4885PIM2 829/4885 |
| US-20120149681-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | PIM1 629/4885PIM3 877/4885PIM2 741/4885 |
| US-20150087632-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | PIM1 700/4885PIM3 950/4885PIM2 829/4885 |
| US-20190135813-A1 | CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | PIM1 700/4885PIM3 950/4885PIM2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.